Evaluating the effect of lipid-apheresis on evinacumab and angiopoietin-like 3 (ANGPTL3) levels

Background and Aims: Patients with homozygous familial hypercholesterolemia (HoFH) have severely elevated LDL-C levels despite the use of multiple pharmacologic lipid-lowering therapies and often require lipid-apheresis. Evinacumab, an ANGPTL3 inhibitor with LDLR-independent activity, has been shown to reduce LDL-C in HoFH patients. To ascertain the impact of lipid-apheresis on circulating drug levels, we conducted an ex-vivo study evaluating the effect of lipid-apheresis on the recovery of evinacumab and ANGPTL3.